Peter Hohenberger

Universität Heidelberg, Heidelburg, Baden-Württemberg, Germany

Are you Peter Hohenberger?

Claim your profile

Publications (324)1465.21 Total impact

  • 12/2015; 5(1). DOI:10.1186/s13569-015-0028-9
  • P Hohenberger, P Reichardt, G Hahn, D Pink, U Schneider
    Zeitschrift für Gastroenterologie 08/2015; 41(08). DOI:10.1055/s-0035-1555196 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction In neoadjuvant therapy, irradiation has a deleterious effect on neoangiogenesis. The aim of this study was to examine the post-implantation effects of neoadjuvant irradiation on the survival and proliferation of autologous cells seeded onto an acellular human dermis (hAD; Epiflex). Additionally, we examined the influence of dermal hair follicle pores on viability and proliferation. We used dorsal skinfold chambers implanted in rats and in-situ microscopy to quantify cell numbers over 9 days. Methods 24 rats received a skinfold chamber and were divided into 2 main groups; irradiated and unirradiated. In the irradiated groups 20Gy were applied epicutaneously at the dorsum. Epiflex pieces were cut to size 5x5mm such that each piece had either one or more visible hair follicle pores, or no such visible pores. Fibroblasts were transduced lentiviral with a fluorescent protein for cell tracking. Ma
    PLoS ONE 05/2015; 10(5-5):e0125689. DOI:10.1371/journal.pone.0125689 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this investigation was to compare different dynamic cell seeding methods regarding their seeding efficiency, homogeneity, infiltration depth and proliferation within a human acellular dermis. In addition, the growth behaviour was observed during a 12-day static in vitro culture. The dynamic methods included orbital-shaker seeding and the use of a plate centrifuge with different rotational speeds, combinations of low-pressure for matrix degassing and centrifugal seeding. Scaffolds were incubated for up to 12 days statically. Cell distribution and infiltration depth were analysed histologically at days 0, 4, 8 and 12. Seeding efficiency and cell proliferation were quantified with the MTT-assay at the same time points. Centrifugal seeding with 300g for 5 × 1 min combined with matrix degassing significantly increased the seeding efficiency and homogeneity compared to the other methods. However, following static culture, no cells were detectable after 4 days in the inner matrix zones. Furthermore, none of the degassing+centrifugation groups reached a significantly higher proliferation at day 8 compared to the reference. The use of a single dynamic method resulted in an inefficient cell seeding. We archived the highest seeding efficiency, homogeneity and infiltration depth using a combination of degassing+centrifugation at 300g for 5 × 1 min.
    Cell and Tissue Banking 03/2015; DOI:10.1007/s10561-015-9508-7 · 1.03 Impact Factor
  • Peter Hohenberger
    The Lancet Oncology 03/2015; 16(4). DOI:10.1016/S1470-2045(15)70125-7 · 24.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Desmoid-type fibromatosis (DF) is a rare monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable clinical course. It may affect nearly all parts of the body including extremities, trunk and abdomen. Considering the variable clinical presentations, anatomic locations and biological behaviours, an individualised treatment approach is required. No established or evidence-based approach for the treatment of this neoplasm is available as of today. Therefore, we propose a consensus treatment algorithm based on a round table meeting bringing together sarcoma experts from the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) with patient advocates from Sarcoma Patients EuroNet (SPAEN). The aim of the meeting was to develop - for the first time ever - a consensus approach based on professionals' AND patients' expertise. As a fundamental prerequisite, all patients should be discussed in a multidisciplinary setting in centres or professional networks with a specific expertise in the disease. Copyright © 2014 Elsevier Ltd. All rights reserved.
    European journal of cancer (Oxford, England: 1990) 01/2015; 51(2):127-36. DOI:10.1016/j.ejca.2014.11.005 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Gastrointestinale Stromatumoren (GIST) sind die häufigste mesenchymale Neoplasie des Gastrointestinaltraktes. Sie unterscheiden sich hinsichtlich Tumorbiologie, Behandlungsstrategie und insbesondere Indikationsstellung zum chirurgischen Vorgehen in wesentlichen Aspekten von gastrointestinalen Karzinomen. Jeder an der Behandlung von GIST beteiligte Chirurg sollte mit diesen Aspekten vertraut sein. Ziel der Arbeit In dieser Arbeit wird der Stellenwert der Positronenemissionstomographie (PET) in der chirurgischen Behandlung von Patienten mit GIST diskutiert und ein Ausblick auf die Entwicklung von auf GIST maßgeschneiderten molekularen Tracern gegeben. Ergebnisse In verschiedenen klinischen Szenarien ist die PET eine wertvolle Hilfe für die Therapieplanung und insbesondere chirurgische Indikationsstellung in der multimodalen Behandlung von GIST. Hervorzuheben sind das Primärstaging, das Monitoring unter neoadjuvanter Therapie sowie das Staging und die Verlaufskontrolle in der metastasierten Situation. Der routinemäßig eingesetzte Tracer ist 18F-FDG, der zuverlässig den Metabolismus von GIST-Läsionen abbildet. Verglichen mit Computertomographie/Magnetresonanztomographie erlaubt das 18F-FDG-PET häufig eine frühere und genauere Responsebeurteilung. GIST-spezifische molekulare Tracer, die eine direkte Prognose zum Therapieansprechen und frühzeitige Informationen zur Resistenzentwicklung liefern könnten, befinden sich in der präklinischen Entwicklung. Hier sind aber noch pharmakokinetische und immunologische Hürden zu überwinden. Fernziel ist die Entwicklung von „theranostics“, also Substanzen, die zugleich diagnostische und therapeutische Zwecke erfüllen. Diskussion In der multimodalen Therapie von GIST und der Indikationsstellung zum chirurgischen Vorgehen hat die PET einen festen Stellenwert.
    coloproctology 01/2015; DOI:10.1007/s00053-015-0525-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of the potential efficacy and safety of combination therapies for advanced soft tissue sarcomas (STS) has increased substantially after approval of trabectedin and pazopanib. Trabectedin's introduction in Europe in 2007 depended mainly on its activity in so-called L-sarcomas (liposarcoma and leiomyosarcoma); combination of trabectedin with other chemotherapies used in STS seems of particular interest. We initiated within the German Interdisciplinary Sarcoma Group (GISG) a phase I dose escalating trial evaluating the combination of trabectedin and gemcitabine in patients with advanced and/or metastatic L-sarcomas (GISG-02; NCT01426633). Patients were treated with increasing doses of trabectedin and gemcitabine. The primary endpoint was to determine the maximum tolerated dose. Five patients were included in the study. Two patients were treated on dose level 1 comprising trabectedin 0.9 mg/m2 on day 1 and gemcitabine 700 mg/m2 on days 1 + 8, every 3 weeks. Due to dose-limiting toxicity (DLT) in both patients (elevated transaminases and thrombocytopenia), an additional three patients were treated on dose level -1 with trabectedin 0.7 mg/m2 plus gemcitabine 700 mg/m2. Of these three patients, two demonstrated another DLT; therefore, the trial was stopped and none of the dose levels could be recommended for phase II testing. The GISG-02 phase I study was stopped with the conclusion that the combination of gemcitabine and trabectedin is generally not recommended for the treatment of patients with advanced and/or metastatic leiomyosarcoma or liposarcoma. Also, this phase I study strongly supports the necessity for careful evaluation of combination therapies.
    Marine Drugs 01/2015; 13(1):379-88. DOI:10.3390/md13010379 · 3.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal stromal tumors (GISTs) spread frequently to the peritoneum and the liver. If metastasectomy or tyrosine kinase inhibitors (TKIs) fail, interventional ablation techniques are considered. The purpose of this study is to assess the progression-free interval (PFI) of GIST liver metastases after radioembolization (RE). Eleven patients with progressive GIST liver metastases undergoing TKI therapy were referred for RE; one was excluded because of a large hepatopulmonary shunt, and one was lost to follow-up. Depending on intrahepatic tumor distribution, one or both liver lobes were treated with RE. Contrast-enhanced magnetic resonance imaging, contrast-enhanced computed tomography (CT), and [(18)F]fluorodeoxyglucose positron-emission tomography/CT were used for follow-up. In all, 16 liver lobes were treated with a mean activity of 1.06 GBq ± 0.37 (range, 0.55-1.88) per lobe. Three patients showed complete response, five showed partial response, and one showed stable disease. No patient showed progressive disease after RE. Median PFI was 15.9 months (range, 4-29 mo). Median survival was 29.8 months (range, 10-72 mo). No radiation-induced liver disease developed; however, one patient required surgery for persistent stomach ulcer. RE offers a safe and effective treatment for patients with GIST liver metastases who do not show a response to TKIs. RE could be an option for earlier phases of therapy in patients with mutational status. The results might also challenge the notion that GISTs are resistant to radiation therapy. Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.
    Journal of vascular and interventional radiology: JVIR 11/2014; 26(2). DOI:10.1016/j.jvir.2014.09.020 · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor control after macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas. Background: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections. Methods: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin) + RHT (>= 5 cycles: 69.7%) versus 73 patients receiving EIA alone (>= 5 cycles: 52.1%, P = 0.027). LPFS and DFS as well as overall survival were determined. Results: RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P = 0.044) and DFS (34% vs 27% after 5 years, P = 0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P = 0.82). Perioperative morbidity and mortality were not significantly different between groups. Conclusions: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
    Annals of Surgery 11/2014; 260(5):749-756. DOI:10.1097/SLA.0000000000000978 · 7.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The EORTC-STBSG coordinated two large trials of adjuvant chemotherapy(CT) in localized high grade soft tissue sarcoma(STS). Both studies failed to demonstrate any benefit on OS. The aim of the analysis of these two trials was to identify subgroups of patients who may benefit from adjuvant CT.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib.METHODS Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months.RESULTSFive factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence-free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5-year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P < .001 for each comparison).CONCLUSIONS The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence. Cancer 2014 © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
    Cancer 08/2014; 120(15). DOI:10.1002/cncr.28669 · 4.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of potential surrogate endpoints for overall survival, such as disease-free-survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCT) in cancer. However, the definition of time-to-event (TTE) endpoints is rarely precise and lacks uniformity across trials. Endpoint definition can impact trial results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE endpoints. We report guidelines for RCT in sarcomas and gastro-intestinal-stromal tumors (GIST).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Association studies have implicated the glycosaminoglycan hyaluronan (hyaluronic acid, HA) and its degrading enzymes the hyaluronidases in tumour progression and metastasis. Oligosaccharides of degraded HA have been ascribed a number of biological functions that are not exerted by high-molecular-weight HA (HMW-HA). However, whether these small HA oligosaccharides (sHA) have a role in tumour progression currently remains uncertain due to an inability to analyse their concentration in tumours.Methods:We report a novel method to determine the concentration of sHA ranging from 6 to 25 disaccharides in tumour interstitial fluid (TIF). Levels of sHA were measured in TIF from experimental rat tumours and human colorectal tumours.Results:While the majority of HA in TIF is HMW-HA, concentrations of sHA up to 6 μg ml(-1) were detected in a subset of tumours, but not in interstitial fluid from healthy tissues. In a cohort of 72 colorectal cancer patients we found that increased sHA concentrations in TIF are associated with lymphatic vessel invasion by tumour cells and the formation of lymph node metastasis.Conclusions:These data document for the first time the pathophysiological concentration of sHA in tumours, and provide evidence of a role for sHA in tumour progression.British Journal of Cancer advance online publication, 17 June 2014; doi:10.1038/bjc.2014.332
    British Journal of Cancer 06/2014; 111(3). DOI:10.1038/bjc.2014.332 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Isolated limb perfusion (ILP) is an effective limb salvage strategy in patients with advanced soft tissue sarcoma (STS) where surgery alone would result in significant functional morbidity or mandate an amputation. Most previous reports of patients undergoing ILP focus on limb salvage rates rather than local and distant relapse rates. Here, we report the oncological outcome of sarcoma patients treated by ILP and surgery. Data were retrieved from prospective ILP databases from two ILP centers following similar ILP techniques and surgical approaches. Only patients with primary, intermediate, or high grade non-metastatic STS were included. The cohort comprised 90 patients. Median follow-up was 39 months (range 3-165 months). Median tumor size was 11 cm (range 5-34). Twenty of 90 (22%) patients underwent prior debulking surgery outside the centers. Twenty-nine of 90 (32%) had postoperative irradiation. Four of 90 underwent amputation either related to local recurrence or irresectability, 4 of 90 underwent amputation for treatment-related complications. Fifteen of 83 (18%) patients had local recurrences after ILP and limb sparing surgery, 39 of 90 (43%) developed metastatic disease. Twenty-two of 90 (24%) died of disease. Preoperative ILP and tumor resection resulted in good local control in a cohort of high-risk STS patients. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 06/2014; 109(8). DOI:10.1002/jso.23591 · 2.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the digestive tract. The GIST differ substantially from gastrointestinal carcinomas regarding tumor biology, treatment strategies and indications for surgery. Every surgeon involved in the treatment of GIST should be acquainted with these aspects. The aims of this article are to discuss the value of positron emission tomography (PET) in the surgical treatment of patients with GIST and to provide an outlook on the development of molecular tracers specifically tailored for GIST. PET is an invaluable decision aid in the multimodal therapy of GIST and particularly for deciding on surgical indications. Specific scenarios in which PET is used are primary staging monitoring during neoadjuvant therapy and staging and response assessment in the metastatic setting. The routinely used tracer is 18F-fluorodeoxyglucose (18F-FDG) and uptake reliably correlates with the metabolism of GIST lesions. Compared to computed tomography and magnetic resonance imaging (CT/MRI), 18F-FDG-PET often allows a more timely and accurate response assessment. GIST-specific molecular tracers, which could provide a direct prognosis regarding response and development of resistance to treatment, are currently in preclinical development. However, pharmacokinetic and immunological issues still need to be resolved. A distant aim is the development of "theranostics", i.e. substances which serve both diagnostic and therapeutic purposes. PET has an established value in the multimodal treatment of GIST and is particularly useful for deciding on surgical indications.
    Der Chirurg 05/2014; DOI:10.1007/s00104-013-2670-1 · 0.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased activity of Src has been found in several human cancers, and often is associated with poor clinical outcome. The present study aimed to determine whether Src activity is increased in gastrointestinal stromal tumors (GIST), and whether it correlates with established tumor or patient characteristics and prognosis. Tumor/normal tissues of 29 patients were analyzed for Src activity/protein with kinase assays, and for VEGF/VEGFR with immunohistochemical staining. Src activity was higher in tumor than in normal tissues (P = 0.093). However, when imatinib responders were excluded from the analyses, it was significantly higher in the tumor tissue (P = 0.017). Additionally, it was higher in primary compared to recurrent tumors or metastasis (P = 0.04). Univariate survival analysis showed a longer overall survival for patients with high Src activity (P = 0.038). In multivariate analysis, the response to imatinib treatment was the only survival-influencing factor (P = 0.072). Src activity is increased in GIST. In contrast to most other tumor entities, it does not correlate with poor clinical outcome, but decreases during the progression from primary tumor to recurrence and metastasis, especially under therapy with imatinib. Additionally, our results show that higher Src activity is associated with longer overall survival. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 05/2014; 109(6). DOI:10.1002/jso.23544 · 2.84 Impact Factor
  • J Jakob, T Henzler, B Kasper, A Marx, P Hohenberger
    [Show abstract] [Hide abstract]
    ABSTRACT: Soft tissue sarcomas are a rare and heterogeneous group of tumors. Surgery clearly remains the standard therapy of non-metastatic soft tissue sarcoma. A pretreatment biopsy is necessary to determine the histology and grade of soft tissue sarcomas and to diagnose entities that can be treated by targeted therapies, such as dermatofibrosarcoma protuberans or alveolar soft tissue sarcoma once they are in a metastatic stage. Nevertheless, locally advanced disease requires multimodal treatment and interdisciplinary treatment decisions. Limb sarcoma of borderline resectability (encasement of vessels, invasion of joints or close proximity to motor nerves) may profit from isolated limb perfusion with recombinant tumor necrosis factor and melphalan. Preoperative chemotherapy may be applied in locally advanced high grade tumors when clear resection margins are difficult to achieve. Deep wave hyperthermia has proven to be a useful addition to systemic chemotherapy in such a neoadjuvant setting. Also preoperative radiation therapy has proven to be effective in controlling locally advanced sarcoma despite higher perioperative morbidity which pays off in the long run by better limb function. Postoperative adjuvant external beam irradiation therapy with the best available technique is recommended for any tumor larger than 5 cm with (FNLCC) grades 2 and 3 (American Joint Committee on Cancer stage IIb/III). Given all these therapeutic options, it is absolutely crucial that interdisciplinary decision-making starts early in the therapeutic process. Patients are often seen first by the surgeon. For an optimal treatment surgeons need to know the efficacy and toxicity of the multimodal treatment options described.
    Der Chirurg 04/2014; 85(5). DOI:10.1007/s00104-013-2689-3 · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Long-term complete remissions remain a rare exception in patients with metastatic gastrointestinal stromal tumors (GIST) treated with IM (imatinib). To date the therapeutic relevance of surgical resection of metastatic disease remains unknown except for the use in palliative intent. Patients and methods We analyzed overall survival (OS) and progression-free survival (PFS) in consecutive patients with metastatic GIST who underwent metastasectomy and received IM therapy (n=239). Results Complete resection (R0+R1) was achieved in 177 patients. Median OS was 8.7y for R0/R1 and 5.3y in pts with R2 resection (p=0.0001). In the group who were in remission at time of resection median OS was not reached in the R0/R1 surgery and 5.1y in the R2-surgery (p=0.0001). Median time to relapse/progression after resection of residual disease was not reached in the R0/R1 and 1.9 years in the R2 group of patients, who were resected in response. No difference in mPFS was seen in patients progressing at time of surgery. Conclusions: Our analysis implicates possible long-term survival in patients in whom surgical complete remission can be achieved. Incomplete resection, including debulking surgery does not seem to prolong survival. Despite the retrospective character and likely selection bias, this analysis may help in decision making for surgical approaches in metastatic GIST.
    European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 04/2014; 40(4). DOI:10.1016/j.ejso.2013.12.020 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale and Objectives To compare in dual-energy CT (DECT) conventionally reconstructed polyenergetic images (PEI) at 120 kVp to virtual monoenergetic images (MEI) at different kiloelectron volt (keV) levels for evaluation of liver and gastrointestinal stromal tumor (GIST) hepatic metastases with regard to objective (IQob) and subjective image quality (IQsub) assessed by two readers of varying experience. Image quality was correlated to patient size and compared between PEI and MEI. Materials and Methods From 50 examinations of 17 GIST patients (12 with hepatic metastases) undergoing abdominal dual-source DECT for staging, therapy monitoring or follow-up, PEI and nine MEI in 10-keV intervals from 40 to 120 keV were reconstructed. Liver contrast-to-noise ratios (CNR) and metastasis-to-liver ratios were calculated. MEI reconstructions with the highest IQob were compared to PEI for IQsub by one experienced reader (ER) and one inexperienced reader (IR). Patients' diameters were correlated to IQob and IQsub ratings. Results MEI at 70 keV had the highest IQob with equal liver CNR and metastasis-to-liver ratio compared to PEI. The ER rated 70-keV MEI and PEI equally high (median 4), whereas the IR rated IQsub best in 70-keV MEI (median 5). Unlike in PEI, IQsub ratings in 70-keV MEI were not correlated to patient size. Conclusions MEI at 70 keV provided an IQob equivalent to PEI. Regarding the IR, IQsub was improved in 70-keV MEI compared to PEI and less dependent on patient size. Therefore, IRs might improve their diagnostic confidence in the assessment of hepatic GIST metastases by evaluating MEI reconstructions at 70 keV.
    Academic Radiology 04/2014; 21(4-4):514-522. DOI:10.1016/j.acra.2014.01.001 · 2.08 Impact Factor

Publication Stats

6k Citations
1,465.21 Total Impact Points


  • 1987–2015
    • Universität Heidelberg
      • • Faculty of Medicine Mannheim and Clinic Mannheim
      • • Department of Spine Surgery
      • • Surgical Hospital
      Heidelburg, Baden-Württemberg, Germany
  • 2010–2014
    • Universitätsmedizin Mannheim
      Mannheim, Baden-Württemberg, Germany
    • HELIOS Klinikum Bad Saarow
      Bad Saarow, Brandenburg, Germany
  • 2007–2014
    • Universität Mannheim
      Mannheim, Baden-Württemberg, Germany
  • 2003–2014
    • Charité Universitätsmedizin Berlin
      Berlín, Berlin, Germany
  • 2013
    • University of Texas MD Anderson Cancer Center
      Houston, Texas, United States
  • 2012
    • Helsinki University Central Hospital
      • Department of Oncology
      Helsinki, Province of Southern Finland, Finland
  • 2006–2010
    • University of Bonn
      • Institut für Pathologie
      Bonn, North Rhine-Westphalia, Germany
  • 2002–2004
    • HELIOS Klinikum Berlin-Buch
      Berlín, Berlin, Germany
  • 1997–2004
    • Humboldt-Universität zu Berlin
      Berlín, Berlin, Germany
  • 1992–2004
    • Max-Delbrück-Centrum für Molekulare Medizin
      Berlín, Berlin, Germany
  • 2000
    • Freie Universität Berlin
      • Department of Hematology
      Berlin, Land Berlin, Germany